Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methotrexate
Drug ID BADD_D01418
Description Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.[A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.[L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198]
Indications and Usage Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150,L10457] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]
Marketing Status approved
ATC Code L01BA01; L04AX03
DrugBank ID DB00563
KEGG ID D00142
MeSH ID D008727
PubChem ID 126941
TTD Drug ID D0SV8E
NDC Product Code 49452-4601; 51927-1565; 0143-9516; 51285-369; 59137-510; 61703-408; 66220-807; 66220-822; 69238-1423; 12780-0491; 46014-1023; 51407-121; 54436-025; 61703-350; 66220-810; 71335-1772; 46014-1005; 16729-277; 0143-9518; 0143-9519; 50268-527; 51079-670; 70771-1058; 70518-1398; 0555-0572; 0143-9367; 66220-815; 70518-3263; 0703-3675; 58623-0040; 0143-9517; 0143-9830; 54436-020; 59137-505; 59137-535; 59137-540; 0378-0014; 66220-825; 42291-505; 47781-482; 52652-2001; 54436-012; 54436-015; 54436-022; 59137-515; 59137-550; 66220-812; 66220-820; 71335-1118; 50090-5457; 51285-368; 54436-010; 59137-520; 59651-182; 68382-775; 0703-3671; 16729-486; 51285-366; 51285-367; 59137-525; 59137-530; 61703-124; 46014-1133; 63660-0006; 66220-817; 70518-3672; 0703-3678; 0904-7141; 54436-017
UNII YL5FZ2Y5U1
Synonyms Methotrexate | Amethopterin | Methotrexate, (D)-Isomer | Methotrexate, (DL)-Isomer | Mexate | Methotrexate Sodium | Sodium, Methotrexate | Methotrexate, Sodium Salt | Methotrexate, Disodium Salt | Methotrexate Hydrate | Hydrate, Methotrexate | Methotrexate, Dicesium Salt | Dicesium Salt Methotrexate
Chemical Information
Molecular Formula C20H22N8O5
CAS Registry Number 59-05-2
SMILES CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mucosal disorder08.01.06.0290.001558%-
Muscle discomfort15.05.03.037---
Myelosuppression01.03.03.0150.002388%-
Nasal mucosal ulcer22.04.03.005---
Near death experience17.02.04.023; 19.10.05.007---
Ocular lymphoma01.15.01.009; 06.08.03.029; 16.28.01.0090.000114%-
Ovarian cancer stage IV16.12.04.008; 21.11.01.021---
Oxidative stress14.11.01.0540.000398%-
Periorbital swelling06.08.03.032; 10.01.05.025; 23.04.01.025---
Pleural thickening22.05.03.0070.000114%-
Portal tract inflammation09.01.07.0380.000114%-
Precancerous condition08.03.04.010---
Primary biliary cholangitis09.01.04.010; 10.04.09.0040.000364%-
Rheumatoid arthritis-associated interstitial lung disease10.04.06.009; 22.01.02.0370.000114%-
Sacral pain15.03.04.023---
Self-consciousness19.05.01.025---
Sensitive skin23.03.03.097---
Sleep deficit17.15.04.010---
Sleep disorder due to a general medical condition19.02.04.003---
Spherocytic anaemia01.06.05.0020.000114%-
Spinal stenosis15.10.04.014; 17.10.01.031---
Stomatitis haemorrhagic07.05.06.013; 24.07.02.0700.000114%-
Subcutaneous drug absorption impaired08.06.01.048; 23.07.04.046---
Surgical failure08.06.01.049---
Swelling of eyelid06.04.04.018; 10.01.05.026; 23.04.01.026---
Symptom recurrence08.01.03.1010.000307%-
Terminal ileitis07.08.01.0220.000114%-
Therapeutic product effect decreased08.06.01.050---
Therapeutic product effect delayed08.06.01.0510.001023%-
Therapeutic product effect incomplete08.06.01.0520.145138%-
The 36th Page    First    Pre   36 37    Next   Last    Total 37 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene